Reconnect Labs
🇨ðŸ‡Switzerland
- Country
- 🇨ðŸ‡Switzerland
- Ownership
- Private
- Established
- 2021-01-01
- Employees
- 11
- Market Cap
- -
- Website
- https://reconnect-labs.com/
Double-Blind, Placebo-Controlled, Crossover Study With Roll-over Extension of Two RE03 Doses for PTSD Sleep Disturbances
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-11-13
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Reconnect Labs
- Target Recruit Count
- 24
- Registration Number
- NCT06685965
- Locations
- 🇨ðŸ‡
Human Sleep Pharmacology, University of Zurich, Zürich, ZH, Switzerland
Dose-finding PKPD Trial for RE02 in Healthy Subjects
- First Posted Date
- 2023-08-07
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Reconnect Labs
- Target Recruit Count
- 4
- Registration Number
- NCT05979727
- Locations
- 🇨ðŸ‡
University Hospital of Psychiatry Zurich, Zürich, ZH, Switzerland
Dose-finding Study for the Combination of DMT and Harmine in Healthy Subjects
- First Posted Date
- 2023-04-25
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- Reconnect Labs
- Target Recruit Count
- 16
- Registration Number
- NCT05829603
- Locations
- 🇨ðŸ‡
University Hospital of Psychiatry Zurich, Zürich, ZH, Switzerland
© Copyright 2024. All Rights Reserved by MedPath